Condition category
Digestive System
Date applied
20/12/2005
Date assigned
20/12/2005
Last edited
03/07/2009
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr A. Lei

ORCID ID

Contact details

Academic Medical Centre
Motility Center
C2 room 311
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

NTR343

Study information

Scientific title

Acronym

Study hypothesis

The Gatekeeper procedure involves the placement of polyacrylonitrile-based hydrogel prostheses into the oesophageal submucosal space of the lower oesophageal sphincter to prevent reflux.

The Gatekeeper Reflux Repair System offers several advantages to using standard surgical repair or other current endoscopic procedures. These advantages include the ability of the clinician to easily place the prostheses, and placement of the prostheses is reversible.

The purpose of this investigation is to demonstrate the intended use of the Medtronic Gatekeeper Reflux Repair System to provide symptomatic relief in subjects diagnosed with gastro-oesophageal reflux disease (GERD).

Ethics approval

Received from the local medical ethics committee

Study design

Multicentre, randomised, single blind, placebo controlled, parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Condition

Gastro-oesophageal reflux disease (GERD)

Intervention

The subjects will be randomised to receive the Endoscopy Gatekeeper prostheses or to the endoscopy sham control group with 96 subjects in the treatment arm and 48 subjects in the sham control arm. At 6 months following the initial implant sham procedure, the blind will be broken for all subjects and those randomised to receive the sham procedure will have the opportunity to receive the Gatekeeper procedure. All subjects will complete Symptom Assessment and Quality of Life questionnaires in the screening procedure and at 6 weeks, 3, 6 12 months and annually until study closure. Upper endoscopy will be performed in the screening procedure and at 3, 6 and 12 months. Oesophageal manometry and 48 hours Bravo pH studies will be performed in the screening procedure and at 6 and 12 months. All subjects must discontinue any PPI therapy at least 7 days prior to study visits. Two weeks after the procedure all subjects will be directed to discontinue their PPI therapy. After discontinuation of PPi's subjects who have persistent symptoms of heartburn or regurgitation may be given anti-reflux medication using the treatment regimen as described in the protocol.

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

Serious device and procedure related adverse device effects (whether anticipated or unanticipated) at six months post-procedure and the subject's associated symptoms of heartburn at six months post-procedure.

Secondary outcome measures

Improved oesophageal pH defined as the total percent of time that pH is less than 4 at six months post Gatekeeper procedure as compared to baseline.

Overall trial start date

13/01/2004

Overall trial end date

12/10/2005

Reason abandoned

Eligibility

Participant inclusion criteria

1. Subjects must be at least 18 years of age
2. Subjects with documented typical symptoms of GERD
3. Female subjects of child bearing potential must have a negative pregnancy test within 1 week before treatment and must agree to use an effective means of birth control during participation in the study
4. Subjects who show symptomatic improvement on PPI and want to discontinue their GERD medication
5. Subjects who have demonstrated a baseline 24 hour ph greater than 4% time with pH less than 4.0
6. Subjects with a baseline GERD-HRQL heartburn score of less than 11 on PPI and greater than 20 off PPI
7. Subjects who have been informed of the nature of the study and have agreed to its provisions and provided ICF, approved by the Institutional Review Board or Medical Ethics Committee of the respective clinical site

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

144

Participant exclusion criteria

1. Classified in anaesthesia risk group, American Society of Anaesthesiologists (ASA) class III - IV
2. Extensive barret's oesophagus (greater than 2 cm)
3. Oesophagitis (grades III - IV)
4. Complaints of dysphagia
5. Oesophageal strictures
6. Oesophageal or gastric varices
7. Previous history of gastro-oesophageal surgery, anti-reflux procedures, or gastro-oesophageal or gastric cancer
8. Large hiatal hernia (greater than 3 cm)
9. Ineffective oesophageal motility, defined as amplitudes of less than 30 mmHg greater than 50% of the time
10. Diagnosed with morbid obesity (body mass index [BMI] greater than 35 kg/m^2)
11. Immunocompromised subjects (subjects diagnosed with human immunodeficiency virus (HIV), on chronic steroid use or other immunosuppressants, such as Immuran)
12. History of bleeding diathesis or coagulopathy or who will refuse blood transfusions
13. Inability to discontinue anticoagulation therapy
14. Suffered a stroke or transient ischemic neurological attack (TIA) within the past 6 months
15. Experienced a haematologically significant gastrointestinal bleed within the past 6 months
16. Has other medical illness that may cause the subject to be non-compliant with or unable to meet the requirements of the protocol or is associated with limited life expectancy
17. Simultaneously participating in another device or drug study, or who has participated in any clinical trial involving an experimental device within 6 months or experimental drug within 30 days of study entry
18. Unable or unwilling to cooperate with study procedures

Recruitment start date

13/01/2004

Recruitment end date

12/10/2005

Locations

Countries of recruitment

Netherlands

Trial participating centre

Academic Medical Centre
Amsterdam
1105 AZ
Netherlands

Sponsor information

Organisation

Academic Medical Centre (AMC) (Netherlands)

Sponsor details

Department of Endoscopy
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Sponsor type

Hospital/treatment centre

Website

http://www.amc.uva.nl

Funders

Funder type

Industry

Funder name

Medtronic Gastroenterology/Urology (MGU) (Netherlands)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes